JPH2 and congestive heart failure: At the same time, many other altered regulatory proteins involving in cardiomyocyte Ca2+ homeostasis could be potential targets for gene therapy in CHF as well, such as phospholamban, junctophilin-2 (JP2), RyRs and NCXs.